Voyageur Pharmaceuticals Ltd. VM.V
TSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 136.17% | -8.95% | 94.18% | 237.10% | -28.71% |
| Depreciation & Amortization | 0.00% | 0.00% | -33.33% | -33.33% | -33.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.49% | -5.96% | 93.50% | 241.15% | -28.71% |
| Operating Income | -136.07% | 8.95% | -93.37% | -237.66% | 28.71% |
| Income Before Tax | -87.47% | 20.08% | -86.11% | -262.78% | 6.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.47% | 20.08% | -86.11% | -262.78% | 6.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.47% | 20.08% | -86.11% | -262.78% | 6.11% |
| EBIT | -136.07% | 8.95% | -93.37% | -237.66% | 28.71% |
| EBITDA | -136.17% | 8.95% | -93.50% | -238.02% | 28.71% |
| EPS Basic | -70.83% | 29.73% | -45.83% | -200.00% | 20.00% |
| Normalized Basic EPS | -66.67% | 30.43% | -46.67% | -200.00% | 21.05% |
| EPS Diluted | -70.83% | 29.73% | -45.83% | -200.00% | 20.00% |
| Normalized Diluted EPS | -66.67% | 30.43% | -46.67% | -200.00% | 21.05% |
| Average Basic Shares Outstanding | 11.08% | 14.83% | 27.96% | 20.08% | 16.05% |
| Average Diluted Shares Outstanding | 11.08% | 14.83% | 27.96% | 20.08% | 16.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |